Safety Alert for Women Taking Postmenopausal Hormone Replacement Therapy

FDA, Center for Drug Evaluation and Research. (2003a). Estrogen and estrogen with progestin therapies for postmenopausal women: FDA approves new labels for estrogen and estrogen with progestin therapies for postmenopausal women following review of Women's Health Initiative data. Retrieved March 1, 2003, from http://www.fda.gov/cder/drug/infopage/estrogens_progestins/default.htm

FDA, Center for Drug Evaluation and Research. (2003b). Questions and answers for estrogen and estrogen with progestin therapies for post-menopausal women. Retrieved March 16, 2003, from http://www.fda.gov/cder/drug/infopage/estrogens_progestins/Q&A.htm

FDA MedWatch. (2003). Safetyalert—Prempro/premphase/premarin. Retrieved March 14, 2003, from http://www.fda.gov/medwatch/SAFETY/2003/prempro.htm

FDA News. (2003). FDA approves new labels for estrogen and estrogen with progestin therapies for postmenopausal women following review of Women's Health Initiative data. Retrieved May 2003 from http://www.fda.gov/bbs/topics/NEWS/2003/NEW00863.html

U.S. Department of Health and Human Services, National Institutes of Health, the National Heart, Lung, and Blood Institute. (2002). NIH news release: NHLBI stops trial of estrogen plus progestin: Due to increased breast cancer risk, lack of overall benefit. Retrieved February 1, 2003, from http://www.nhlbi.nih.gov/new/press/02-07-09.htm

The Women's Health Initiative Study Investigators, U.S. Department of Health and Human Services, National Institutes of Health, the National Heart, Lung, and Blood Institute. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA-Express, 288(3). Retrieved January, 28, 2003, from http://jama.ama-assn.org/issues/v288n3/ffull/joc21036.html